Disparities in Survival Outcomes Between Locally Advanced Cervical Squamous Cell Carcinoma and Adenocarcinoma Treated with Chemoradiotherapy
Shan-Shan Hong,Yang Li,Yu-Yi Lin,San-Gang Wu,Li-Ying Chen,Juan Zhou
DOI: https://doi.org/10.2147/ijwh.s450457
2024-03-07
International Journal of Women s Health
Abstract:Shan-Shan Hong, 1, &ast Yang Li, 2, &ast Yu-Yi Lin, 3 San-Gang Wu, 4 Li-Ying Chen, 1 Juan Zhou 5 1 Department of Obstetrics and Gynecology, Quanzhou Women's and Children's Hospital, Quanzhou, 362000, People's Republic of China; 2 School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, People's Republic of China; 3 Department of Radiation Oncology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen, 361021, People's Republic of China; 4 Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China; 5 Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li-Ying Chen, Department of Obstetrics and Gynecology, Quanzhou Women's and Children's Hospital, Quanzhou, 362000, People's Republic of China, Email Juan Zhou, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China, Email Purpose: To determine the disparities in survival outcomes between stage IIB-IVA cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) treated with chemoradiotherapy. Methods: Patients diagnosed between 2004 and 2015 were retrospectively included from the Surveillance, Epidemiology, and End Results databases. Propensity score matching (PSM) was used in this study. The primary endpoints were cervical cancer-specific survival (CCSS) and overall survival (OS). Results: A total of 2752 patients were identified, including 87.5% (n=2408) were SCC and 12.5% (n=344) were AC. Patients with AC had inferior 5-year CCSS (67.5% vs 54.8%, P< 0.001) and OS (58.4% vs 47.2%, P< 0.001) compared to those with the SCC subtype. The hazard curve of cervical cancer-related death in AC peaked at 2 years (19%) and still small peaks in the 7 and 11 years of follow-up. Regarding SCC, cervical cancer-related deaths peaked at 2 years (15%) and the hazard rate was 2.0% during the six years of follow-up. The multivariate Cox regression analyses indicated that histology was an independent prognostic factor associated with survival outcomes. Patients with AC had significantly poor CCSS (P< 0.001) and OS (P< 0.001). Similar results were found after PSM. Conclusion: Our study demonstrates a significantly better prognosis for cervical SCC patients compared to those with cervical AC undergoing chemoradiotherapy. These results highlight the importance of histological subtyping in predicting treatment outcomes and tailoring therapeutic strategies. Keywords: cervical cancer, squamous cell carcinoma, adenocarcinoma, chemotherapy, radiotherapy, hazard curve Cervical cancer (CC) represents an important global health issue and remains the main cause of cancer-related deaths in women. There are approximately 604,217 new cases of CC worldwide annually, including 111,820 cases in China. 1,2 It is a heterogeneous disease that can be classified into various histological subtypes, with the most common being squamous cell carcinoma (SCC) (70%), followed by adenocarcinoma (AC) (10–25%). 3–5 SCC originates from the squamous epithelium of the cervix, while AC arises from the glandular cells. Tumors containing glandular elements are associated with resistance to radiotherapy and poorer survival outcomes. 6,7 In those receiving definitive radiotherapy or postoperative radiotherapy, several studies have shown AC patients had a higher risk of pelvic recurrence and a lower survival outcome than those in the SCC group both in early- and locally advanced-stage CC. 8,9 Moreover, several studies also have highlighted the distinct biological characteristics of cervical AC and SCC, suggesting potential variations in growth patterns, response to therapies, and likelihood of metastasis. 10–13 These findings indicated that the clinical behavior of the tumor cells and the effectiveness of radiotherapy may be different between SCC and AC. In the current treatment guidelines for stage IIB-IVA CC, concurrent chemoradiotherapy (CCRT) is a widely accepted treatment approach for this patient setting and the recommended treatment strategies for SCC are similar to those with AC. 14–16 In our previous study, we found that the survival of the cervical AC who received definitive radiotherapy had an -Abstract Truncated-
obstetrics & gynecology